Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | thioredoxin reductase | 0.0099 | 0.254 | 1 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.0051 | 0.0882 | 0.114 |
Mycobacterium tuberculosis | Probable nitrite reductase [NAD(P)H] large subunit [FAD flavoprotein] NirB | 0.0225 | 0.6906 | 0.8837 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.0051 | 0.0882 | 0.114 |
Plasmodium vivax | thioredoxin reductase, putative | 0.0099 | 0.254 | 1 |
Trypanosoma cruzi | trypanothione reductase, putative | 0.0099 | 0.254 | 1 |
Wolbachia endosymbiont of Brugia malayi | dihydrolipoamide dehydrogenase E3 component | 0.0034 | 0.0313 | 0.5 |
Leishmania major | trypanothione reductase | 0.0099 | 0.254 | 1 |
Mycobacterium tuberculosis | Probable membrane NADH dehydrogenase NdhA | 0.0225 | 0.6906 | 0.8837 |
Plasmodium falciparum | glutathione reductase | 0.0099 | 0.254 | 1 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0249 | 0.7736 | 1 |
Mycobacterium tuberculosis | NADPH-dependent mycothiol reductase Mtr | 0.0099 | 0.254 | 0.2985 |
Trichomonas vaginalis | mercuric reductase, putative | 0.0034 | 0.0313 | 0.5 |
Plasmodium vivax | glutathione reductase, putative | 0.0099 | 0.254 | 1 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0035 | 0.0328 | 0.0424 |
Brugia malayi | MH2 domain containing protein | 0.0249 | 0.7736 | 1 |
Mycobacterium tuberculosis | Putative ferredoxin reductase | 0.0225 | 0.6906 | 0.8837 |
Mycobacterium tuberculosis | Probable oxidoreductase | 0.025 | 0.7773 | 1 |
Mycobacterium ulcerans | flavoprotein disulfide reductase | 0.0034 | 0.0313 | 0.5 |
Echinococcus multilocularis | thioredoxin glutathione reductase | 0.0099 | 0.254 | 1 |
Mycobacterium tuberculosis | Dihydrolipoamide dehydrogenase LpdC (lipoamide reductase (NADH)) (lipoyl dehydrogenase) (dihydrolipoyl dehydrogenase) (diaphoras | 0.025 | 0.7773 | 1 |
Loa Loa (eye worm) | thioredoxin reductase | 0.0099 | 0.254 | 0.2986 |
Chlamydia trachomatis | dihydrolipoyl dehydrogenase | 0.0034 | 0.0313 | 0.5 |
Mycobacterium tuberculosis | Probable dehydrogenase | 0.0225 | 0.6906 | 0.8837 |
Trichomonas vaginalis | glutathione reductase, putative | 0.0034 | 0.0313 | 0.5 |
Giardia lamblia | NADH oxidase lateral transfer candidate | 0.0034 | 0.0313 | 0.5 |
Plasmodium falciparum | thioredoxin reductase | 0.0099 | 0.254 | 1 |
Brugia malayi | dihydrolipoyl dehydrogenase, mitochondrial precursor, putative | 0.0034 | 0.0313 | 0.0405 |
Mycobacterium tuberculosis | Probable reductase | 0.0225 | 0.6906 | 0.8837 |
Mycobacterium leprae | DIHYDROLIPOAMIDE DEHYDROGENASE LPD (LIPOAMIDE REDUCTASE (NADH)) (LIPOYL DEHYDROGENASE) (DIHYDROLIPOYL DEHYDROGENASE) (DIAPHORASE | 0.025 | 0.7773 | 1 |
Loa Loa (eye worm) | glutathione reductase | 0.0099 | 0.254 | 0.2986 |
Mycobacterium ulcerans | dihydrolipoamide dehydrogenase, LpdB | 0.0034 | 0.0313 | 0.5 |
Mycobacterium tuberculosis | NAD(P)H quinone reductase LpdA | 0.025 | 0.7773 | 1 |
Brugia malayi | glutathione reductase | 0.0099 | 0.254 | 0.3284 |
Brugia malayi | Thioredoxin reductase | 0.0099 | 0.254 | 0.3284 |
Trypanosoma brucei | trypanothione reductase | 0.0099 | 0.254 | 1 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.0051 | 0.0882 | 0.0747 |
Mycobacterium ulcerans | dihydrolipoamide dehydrogenase | 0.0034 | 0.0313 | 0.5 |
Echinococcus granulosus | thioredoxin glutathione reductase | 0.0099 | 0.254 | 1 |
Treponema pallidum | NADH oxidase | 0.0034 | 0.0313 | 0.5 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0249 | 0.7736 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0035 | 0.0328 | 0.0015 |
Mycobacterium tuberculosis | Probable NADH dehydrogenase Ndh | 0.0225 | 0.6906 | 0.8837 |
Wolbachia endosymbiont of Brugia malayi | dihydrolipoamide dehydrogenase E3 component | 0.0034 | 0.0313 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0051 | 0.0882 | 0.0747 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.